Ixifi Drug Interactions

Specific drug interaction studies have not been conducted with IXIFI.
In rheumatoid arthritis and Crohn's disease patients, there are indications that concomitant use of methotrexate and other immunomodulators reduces the formation of antibodies against infliximab and increases the plasma concentrations of infliximab. However, the results are uncertain due to limitations in the methods used for serum analyses of infliximab and antibodies against infliximab.
Corticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant extent.
The combination of IXIFI with other biological therapeutics used to treat the same conditions as IXIFI, including anakinra and abatacept, is not recommended (see Precautions).
Live Vaccines/Therapeutic Infectious Agents: It is recommended that live vaccines not be given concurrently with IXIFI. It is also recommended that live vaccines not be given to infants after in utero exposure to infliximab for 12 months following birth, unless infliximab exposure was limited to the first trimester or if infant infliximab serum levels are undetectable. Administration of a live vaccine prior to 12 months of age might be considered if the benefit of the vaccination clearly outweighs the theoretical risk of administration of live vaccines to the infants (see Precautions).
Administration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not recommended unless infant infliximab serum levels are undetectable (see Precautions and Use in Pregnancy & Lactation).
It is recommended that therapeutic infectious agents not be given concurrently with IXIFI (see Precautions).